Summary: New research from the University of Pennsylvania shows that psilocybin, the active compound in certain psychedelic mushrooms, can reduce chronic pain and pain-related depressive behavior by altering brain circuits rather than acting at the injury site. In mouse models, a single dose produced both pain relief and mood improvement that persisted for nearly two weeks by targeting the anterior cingulate cortex.
Unlike many conventional medications, psilocybin fine-tunes serotonin signaling rather than fully switching receptors on or off, offering a balanced approach to relieving pain and low mood without the addiction risks associated with opioids. These findings point toward non-opioid treatment strategies that address both pain and mood disorders together.
Key Facts:
- Dual Relief: In mouse models, a single dose of psilocybin reduced persistent pain and associated anxiety- and depression-like behaviors.
- Targeted Action: The therapeutic effects were driven by modulation of circuits in the anterior cingulate cortex (ACC), not by actions at the spinal cord or other peripheral injury sites.
- Therapeutic Potential: Results support psilocybin’s promise as a non-opioid, non-addictive option for managing chronic pain and comorbid mood symptoms.
Source: University of Pennsylvania
Researchers at Penn Medicine have mapped the brain circuits affected by psilocybin, opening new possibilities for treating chronic pain and related mood disorders.
Chronic pain affects more than 1.5 billion people worldwide and frequently coexists with depression and anxiety, creating a cycle that intensifies suffering and reduces quality of life. The new study from the Perelman School of Medicine, published in Nature Neuroscience, identifies neural mechanisms by which psilocybin may interrupt that cycle.
Joseph Cichon, MD, PhD, an assistant professor of Anesthesiology and Critical Care at Penn and senior author of the study, notes that many patients experience intertwined pain and mood symptoms and are uncertain which began first. The new findings suggest a single, targeted intervention could alleviate both problems simultaneously without relying on addictive substances.
Targeting the Brain’s Pain and Mood Hub
In experiments using mice with chronic nerve injury and inflammatory pain, researchers observed that one dose of psilocybin produced rapid reductions in mechanical hypersensitivity (allodynia) and in anxiety- and depression-like behaviors. These benefits lasted for nearly two weeks after treatment. Mechanistically, psilocybin acts by activating serotonin receptors—primarily 5-HT2A and 5-HT1A—in a partial, modulatory manner rather than as a full agonist.
To locate where psilocybin exerts its therapeutic effects, the team administered psilocin (the active metabolite of psilocybin) directly into different regions of the central nervous system. Using advanced fluorescent imaging to observe neuronal activity in real time, they found that injecting psilocin into the prefrontal cortex—specifically the anterior cingulate cortex (ACC), a region central to pain and emotional processing—reproduced the systemic benefits seen with whole-body administration. In contrast, similar injections into the spinal cord did not produce the same calming effect on pain-related neuronal hyperactivity or behavior.
Two-photon calcium imaging revealed that psilocin rapidly normalized the excessive firing of layer 2/3 pyramidal neurons in the ACC that is associated with chronic pain. Pharmacologic tests showed that full agonists at 5-HT2A and 5-HT1A receptors could mimic some of psilocin’s effects but not all, supporting the idea that partial agonism at these receptors within shared circuits underlies the concurrent relief of pain and mood symptoms.
“Psilocybin may provide meaningful relief by bypassing the injured tissue and instead adjusting the brain circuits that interpret pain and regulate mood,” said Cichon. “That dual action—reducing pain sensitivity while lifting low mood—could offer a new therapeutic avenue that avoids the risks associated with opioids.”
Implications and Next Steps
The researchers believe these results can guide the development of new treatments for other conditions involving dysregulated brain circuits, such as addiction or post-traumatic stress disorder. However, Cichon and colleagues stress that more research is needed to evaluate safety, dosing, and long-term effects—especially in clinical contexts such as surgery and anesthesia where stress can worsen both pain and mood symptoms.
The Penn team plans additional studies in rodent models to refine dosing strategies, measure how durable the benefits are, and investigate whether repeated treatments can produce longer-lasting rewiring of brain pathways involved in chronic pain.
“These findings are encouraging, but questions remain about how long psilocybin’s benefits persist and whether multiple doses are required to sustain changes in the neural circuits that drive chronic pain,” said Stephen Wisser, a Penn Neuroscience PhD student and co-author.
Funding: The study was supported by the National Institutes of Health (R35GM151160-01) and the American Society of Regional Anesthesia and Pain Medicine (ASRA) Chronic Pain Medicine Research Award.
Key Questions Answered:
A: The team found that psilocybin modulates circuits in the anterior cingulate cortex to reduce chronic pain sensitivity and improve anxiety- and depression-like behaviors in mouse models.
A: Rather than fully activating or blocking serotonin receptors, psilocybin (via its active metabolite psilocin) acts as a partial agonist that gently adjusts 5-HT2A and 5-HT1A receptor activity, similar to a dimmer switch.
A: The results suggest a potential non-opioid, non-addictive strategy to simultaneously address chronic pain and mood disorders by targeting the brain circuits that coordinate sensory and emotional aspects of pain.
About this psilocybin, pain, and depression research news
Author: Matthew Toal
Source: University of Pennsylvania
Contact: Matthew Toal – University of Pennsylvania
Image: The image is credited to Neuroscience News
Original Research: Open access. “Single-dose psilocybin rapidly and sustainably relieves allodynia and anxiodepressive-like behaviors in mouse models of chronic pain” by Joseph Cichon et al., Nature Neuroscience.
Abstract
Single-dose psilocybin rapidly and sustainably relieves allodynia and anxiodepressive-like behaviors in mouse models of chronic pain
Chronic pain and mood disorders often co-occur, worsen one another, and share underlying neurobiological mechanisms. Whether one intervention can quickly and durably reverse both conditions has been unclear. In two mouse models of chronic pain, a single dose of psilocybin produced rapid and sustained reductions in mechanical allodynia and in anxiety- and depression-like states in both male and female adult mice.
Using localized psilocin injections, the study demonstrates that engagement of prefrontal cortical circuits—particularly those within the anterior cingulate cortex—is essential for concurrently alleviating pain and mood symptoms. Two-photon calcium imaging showed that psilocin rapidly normalizes pain-associated hyperactivity in ACC layer 2/3 pyramidal neurons. Pharmacological experiments with full agonists at 5-HT2A and 5-HT1A receptors reproduced some but not all of psilocin’s cellular and behavioral effects, supporting the idea that psilocin’s partial agonism at these receptors within shared circuits underlies its dual therapeutic action.